SOX2 and glioblastoma: When we studied whether stem cell markers are predictors of outcome in subsets of patients with GBM based on MGMT methylation status, we uncovered a remarkable relationship: MGMT methylation was a predictor of outcome only in tumors with strong levels of expression of SOX2 or CD133, and not in tumors with low or absent SOX2 and CD133 expression.